Abstract:Hepatocellular carcinoma (HCC) is one of the most common types of cancer. Despite decades of research efforts, the search for novel biomarkers is still urgently needed for the diagnosis of HCC and the improvement of clinical outcomes. Previous studies of HCC clinical biomarkers have usually focused on serum and urine samples (e.g., serum Alpha-fetoprotein (AFP). However, cellular membrane proteins in lesion tissues are less used in HCC diagnosis. The abnormal expression of membrane glycoproteins in tumor lesions are considered as potential targets for tumor diagnosis and tumor therapies. Here, a lectin array has been employed to screen and identify abnormal glycopatterns and cellular membrane glycans in HCC lesion tissues compared with adjacent non-tumor tissues. We found that there was significantly less expression of Erythrina cristagalli (ECA) lectin binding (Galβ1-3/β1-4) glycans on the cellular membrane of HCC lesion tissues compared with those of adjacent non-tumor tissues. Immunohistochemistry analysis further showed that ECA-binding ability on the membrane proteins of HCC tissues progressively decreased in different tumor-node-metastasis (TNM) stages (stage I to stage III) as the malignancy of liver cancer increased. Receiver operating curve (ROC) analysis showed ECA-binding ability yielding a sensitivity of 85% and specificity of 75%, and a combination of ECA and AFP has better clinical diagnostic efficiency, yielding a sensitivity of 90% and specificity of 85%, than ECA or AFP assay alone. ECA pull-down followed by mass spectrometry further showed that there was significantly less expression of ECA binding membrane catalase (CAT) and prolyl 4-hydroxylase beta polypeptide (P4HB) in HCC tissues compared with the adjacent non-tumor tissues. The abnormally increased expression of total CAT and P4HB and decreased expression of galactosylated membrane CAT and P4HB in HCC cell lines were correlated with an HCC metastasis status. Our findings suggest that abnormal declined ECA-binding galatosylated membrane glycans and two galactosylated-CAT and P4HB glycoproteins in lesion tissues are potential biomarkers in the diagnosis and/or metastasis prediction for HCC.

[An Analysis of Annexin II Related to HCC Metastatic Ability].

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Identification and Analysis of Altered Alpha 1,6-Fucosylated Glycoproteins Associated with Hepatocellular Carcinoma Metastasis

Annexin II Promotes Invasion and Migration of Human Hepatocellular Carcinoma Cells in Vitro Via Its Interaction with HAb18G/CD147

Alteration of Ck8 Both in Its Expression Level and Its Glycan Parts Related to Hcc Metastatic Ability

[Effects of Annexin A2 gene transcription down-regulation on human hepatoma cell biological behaviour]

[Dysregulation of Annexin II Expression in Esophageal Squamous Cell Cancer and Adjacent Tissues from a High-Incidence Area for Esophageal Cancer in Henan Province].

[The Expression and Clinical Significance of Annexin II in Clear-Cell Renal Cell Carcinoma].

Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma

Lectin-based Glycoproteomics to Explore and Analyze Hepatocellular Carcinoma-Related Glycoprotein Markers.

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Annexin A2 Promotes the Migration and Invasion of Human Hepatocellular Carcinoma Cells in Vitro by Regulating the Shedding of CD147-Harboring Microvesicles from Tumor Cells

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Comparative serum glycoproteomics of non-metastatic and metastatic hepatocellular carcinoma by lectin affinity technology

Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Core-Fucosylated Glycoproteomics Correlated with the Metastasis of Hepatoma

Annexin A2 is Not A Good Biomarker for Hepatocellular Carcinoma in Cirrhosis

Proteome Analysis of Hepatocellular Carcinoma Cell Strains, MHCC97-H and MHCC97-L, with Different Metastasis Potentials.

Fucosylated Glycans Associated With Development and Metastasis of Hepatocellular Carcinoma Cells: Fucosylated Glycans Associated With Development and Metastasis of Hepatocellular Carcinoma Cells

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

[Serum proteomic analysis on metastasis-associated proteins of hepatocellular carcinoma]